LON:OXB opened at GBX 697.07 ($9.11) on Tuesday. The company has a debt-to-equity ratio of 124.13, a current ratio of 2.25 and a quick ratio of 2.05. Oxford BioMedica has a 12-month low of GBX 511 ($6.68) and a 12-month high of GBX 1,062.60 ($13.88). The stock has a market cap of $452.99 million and a P/E ratio of -871.34.
In other news, insider Andrew Heath purchased 2,000 shares of the business’s stock in a transaction on Monday, February 4th. The stock was acquired at an average price of GBX 709 ($9.26) per share, for a total transaction of £14,180 ($18,528.68). Also, insider Lorenzo Tallarigo purchased 413 shares of the business’s stock in a transaction on Monday, February 25th. The shares were purchased at an average price of GBX 644 ($8.42) per share, with a total value of £2,659.72 ($3,475.40). Insiders have purchased 4,418 shares of company stock valued at $2,944,060 in the last quarter.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Recommended Story: How Buying a Call Option Works
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.